Zara Izadi

List of Publications by Year
in descending order

27 papers	2,090 citations	687363 13 h-index	552781 26 g-index
30 all docs	30 docs citations	30 times ranked	3538 citing authors

#	Article	IF	Citations
1	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2020, 79, 859-866.	0.9	908
2	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals of the Rheumatic Diseases, 2021, 80, 930-942.	0.9	496
3	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Annals of the Rheumatic Diseases, 2021, 80, 1137-1146.	0.9	151
4	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	5.9	86
5	Association of Race and Ethnicity With COVID‑19 Outcomes in Rheumatic Disease: Data From the COVID‑19 Global Rheumatology Alliance Physician Registry. Arthritis and Rheumatology, 2021, 73, 374-380.	5.6	66
6	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
7	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatology, The, 2021, 3, e855-e864.	3.9	38
8	Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs. Seminars in Arthritis and Rheumatism, 2019, 48, 1087-1092.	3.4	37
9	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. RMD Open, 2022, 8, e002187.	3.8	34
10	Patient-reported outcome measures for use in clinical trials of SLE: a review. Lupus Science and Medicine, 2018, 5, e000279.	2.7	32
11	Socioeconomic Disparities in Functional Status in a National Sample of Patients With Rheumatoid Arthritis. JAMA Network Open, 2021, 4, e2119400.	5.9	29
12	Discordance of the Framingham cardiovascular risk score and the 2013 American College of Cardiology/American Heart Association risk score in systemic lupus erythematosus and rheumatoid arthritis. Clinical Rheumatology, 2018, 37, 467-474.	2.2	21
13	A Pilot Study of Use of a Software Platform for the Collection, Integration, and Visualization of Diabetes Device Data by Health Care Providers in a Multidisciplinary Pediatric Setting. Diabetes Technology and Therapeutics, 2018, 20, 806-816.	4.4	20
14	RISE registry reveals potential gaps in medication safety for new users of biologics and targeted synthetic DMARDs. Seminars in Arthritis and Rheumatism, 2020, 50, 1542-1548.	3.4	15
15	Significant Gains in Rheumatoid Arthritis Quality Measures Among RISE Registry Practices. Arthritis Care and Research, 2022, 74, 219-228.	3.4	14
16	Capturing a Patient-Reported Measure of Physical Function Through an Online Electronic Health Record Patient Portal in an Ambulatory Clinic: Implementation Study. JMIR Medical Informatics, 2018, 6, e31.	2.6	14
17	Race, Ethnicity, and Disparities in the Risk of End‑Organ Lupus Manifestations Following a Systemic Lupus Erythematosus Diagnosis in a Multiethnic Cohort. Arthritis Care and Research, 2023, 75, 34-43.	3.4	13
18	Hydroxychloroquine dosing in immune-mediated diseases: implications for patient safety. Rheumatology International, 2017, 37, 1611-1618.	3.0	11

#	Article	IF	Citations
19	Epidemiology and treatment of Behçet's disease in the USA: insights from the Rheumatology Informatics System for Effectiveness (RISE) Registry with a comparison with other published cohorts from endemic regions. Arthritis Research and Therapy, 2021, 23, 224.	3.5	10
20	Development of a Natural Language Processing System for Extracting Rheumatoid Arthritis Outcomes From Clinical Notes Using the National Rheumatology Informatics System for Effectiveness Registry. Arthritis Care and Research, 2023, 75, 608-615.	3.4	10
21	Effects of Language, Insurance, and Race/Ethnicity on Measurement Properties of the PROMIS Physical Function Short Form 10a in Rheumatoid Arthritis. Arthritis Care and Research, 2019, 71, 925-935.	3.4	9
22	Three Quality Improvement Initiatives and Performance of Rheumatoid Arthritis Disease Activity Measures in Electronic Health Records: Results From an Interrupted Time Series Study. Arthritis Care and Research, 2020, 72, 283-291.	3.4	7
23	Health‐Related Quality of Life Measures in Adult Systemic Lupus Erythematosus. Arthritis Care and Research, 2020, 72, 577-592.	3.4	7
24	Factors Associated With Hospitalization and Death After COVID‐19 Diagnosis Among Patients With Rheumatic Disease: An Analysis of Veterans Affairs Data. ACR Open Rheumatology, 2021, 3, 796-803.	2.1	5
25	Gaps in Ambulatory Patient Safety for Immunosuppressive Specialty Medications. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 348-357.	0.7	4
26	The Relationship Between Electronic Health Record System and Performance on Quality Measures in the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) Registry: Observational Study. JMIR Medical Informatics, 2021, 9, e31186.	2.6	4
27	Towards the patient-centred care of rheumatoid arthritis. Nature Reviews Rheumatology, 0, , .	8.0	0